Professor Jacky
Smith will present on the reduction of cough bouts with
nalbuphine ER observed in patients with IPF in the CANAL
trial
NEW
HAVEN, Conn., April 9,
2024 /PRNewswire/ -- Trevi Therapeutics,
Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical
company developing the investigational therapy Haduvio™ (oral
nalbuphine ER) for the treatment of chronic cough in idiopathic
pulmonary fibrosis (IPF) and refractory chronic cough (RCC), today
announced that data from the Phase 2 CANAL trial will be presented
at the American Thoracic Society (ATS) 2024 International
Conference being held in San Diego,
CA, from May 17-22. The
presentation will take place on May
19th.
Trevi CANAL trial data being presented on
May 19 at American Thoracic Society
Conference
ATS 2024 International
Conference
May 17-22, 2024,
San Diego, CA
Session: A104: Advances in the Diagnosis and Treatment
of ILD
Abstract: Nalbuphine Extended-release Reduces Cough Bouts in
Patients With Idiopathic Pulmonary Fibrosis
Presentation: May 19,
3:00 p.m. - 4:15 p.m. PT
Location: San Diego
Convention Center, Room 33A-C (Upper Level)
Presenter: Jacky Smith, MB,
ChB, FRCP, PhD, Professor of
Respiratory Medicine at the University of Manchester, and an Honorary Consultant at
Manchester University NHS
Foundation Trust. Director of the NIHR
Manchester Clinical Research Facility, Respiratory Theme Lead
in the NIHR Manchester Biomedical Research Centre and
an NIHR Senior Investigator.
Registration details: https://conference.thoracic.org/
About Trevi Therapeutics, Inc.
Trevi Therapeutics, Inc. is a clinical-stage biopharmaceutical
company developing the investigational therapy Haduvio™ (oral
nalbuphine ER) for the treatment of chronic cough in idiopathic
pulmonary fibrosis (IPF) and refractory chronic cough (RCC). Trevi
is also developing Haduvio for prurigo nodularis. Haduvio is a dual
ĸ-opioid receptor agonist and µ-opioid receptor antagonist that
works both centrally in the brain as well as peripherally in the
lungs and has the potential for a synergistic antitussive effect to
treat chronic cough.
The impact of chronic cough is significant and often leads to a
decline in patients' social, physical, and psychological quality of
life. In IPF, chronic cough may lead to worsening disease and may
be associated with a higher risk of progression, death, or need for
lung transplant. There are no approved therapies for the treatment
of chronic cough in IPF and current treatment options provide
minimal relief to patients. RCC affects up to 10% of the adult
population, and Haduvio's expansion into RCC has the potential to
reach patients suffering from moderate to severe chronic cough.
There are also no approved therapies for RCC in the US.
Parenteral nalbuphine is not scheduled by the U.S. Drug
Enforcement Agency. Trevi intends to propose Haduvio as the trade
name for oral nalbuphine ER. Its safety and efficacy have not been
evaluated by any regulatory authority.
For more information, visit www.TreviTherapeutics.com and
follow Trevi on X (formerly Twitter) and LinkedIn.
Investor Contact
Katie
McManus
Trevi Therapeutics, Inc.
203-304-2499
k.mcmanus@trevitherapeutics.com
Media Contact
Rosalia
Scampoli
914-815-1465
rscampoli@marketcompr.com
View original content to download
multimedia:https://www.prnewswire.com/news-releases/trevi-therapeutics-announces-abstract-presentation-at-the-american-thoracic-society-2024-international-conference-302111290.html
SOURCE Trevi Therapeutics, Inc.